SKYE vs UFG Comparison

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Uni-Fuels Holdings Ltd is a service provider of marine fuel solutions. It operates on an integrated business model, serving customers through two operating models: sales of marine fuels solutions and brokerage (i.e., acting as an intermediary between marine fuels suppliers and customers for a commission). The various marine fuel products offered by the company include very low sulfur fuel oil, high sulfur fuel oil, marine gas oil, and bio marine fuel. Its customers are mainly shipping companies and other fuel suppliers operating in market sectors such as bulk, tanker, offshore, container, general cargo, tug and barge, car carrier, cruise, yacht, and dredging. Geographically, the company derives maximum revenue from Singapore, and the rest from Malaysia, Hong Kong, China, and other regions.